1. Document reveals scope of Operation Warp Speed and underscores vast military involvement — New data bolsters Sarepta gene therapies for two deadly muscle diseases — Inovio forced to delay planned phase 2/3 testing of COVID vaccine — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

COVID-19 beneficial for Mylan, A visual treat of earnings

Discussion in 'Mylan/Bertek' started by anonymous, May 11, 2020 at 9:06 AM.

  1. anonymous

    anonymous Guest

    Mylan N.V. (MYL) reported its financial results for the quarter ended March 31, 2020, on Monday before the market opens. The company reaffirmed its financial guidance for the full-year 2020.

    The results were driven by overall volume growth, which was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic, primarily in its Europe segment.

    Looking ahead, Mylan remains on track to close the pending combination with Pfizer’s Upjohn Business in the second half of the year.

    Take a look at the company's earnings in graphical format here